Association Between Fecal Calprotectin Levels and Small-bowel Inflammation Score in Capsule Endoscopy : A Multicenter Retrospective Study
(2016) In Digestive Diseases and Sciences 61(7). p.2033-2040- Abstract
BACKGROUND: Accurate inflammation reporting in capsule endoscopy (CE) is important for diagnosis and monitoring of treatment of inflammatory bowel disease (IBD). Fecal calprotectin (FC) is a highly specific biomarker of gut inflammation. Lewis score (LS) was developed to standardize quantification of inflammation in small-bowel (SB) CE images.
GOALS: Multicenter retrospective study aiming to investigate correlation between LS and FC in a large group of patients undergoing CE for suspected or known small-bowel IBD, and to develop a model for prediction of CE results (LS) based on FC levels.
STUDY: Five academic centers and a district general hospital offering CE in UK, Finland, Sweden, Canada, and Israel. In total, 333... (More)
BACKGROUND: Accurate inflammation reporting in capsule endoscopy (CE) is important for diagnosis and monitoring of treatment of inflammatory bowel disease (IBD). Fecal calprotectin (FC) is a highly specific biomarker of gut inflammation. Lewis score (LS) was developed to standardize quantification of inflammation in small-bowel (SB) CE images.
GOALS: Multicenter retrospective study aiming to investigate correlation between LS and FC in a large group of patients undergoing CE for suspected or known small-bowel IBD, and to develop a model for prediction of CE results (LS) based on FC levels.
STUDY: Five academic centers and a district general hospital offering CE in UK, Finland, Sweden, Canada, and Israel. In total, 333 patients were recruited. They had small-bowel CE and FC done within 3 months.
RESULTS: Overall, correlation between FC and LS was weak (r s: 0.232, P < 0.001). When two clinically significant FC thresholds (100 and 250 μg/g) were examined, the r s between FC and LS was 0.247 (weak) and 0.337 (moderate), respectively (P = 0.307). For clinically significant (LS ≥ 135) or negative (LS < 135) for SB inflammation, ROC curves gave an optimum cutoff point of FC 76 μg/g with sensitivity 0.59 and specificity 0.41.
LIMITATIONS: Retrospective design.
CONCLUSIONS: LS appears to show low correlation with FC as well as other serology markers of inflammation. FC does not appear to be a reliable biomarker for significant small-bowel inflammation. Nevertheless, FC level ≥ 76 μg/g may be associated with appreciable visual inflammation on small-bowel CE in patients with negative prior diagnostic workup.
(Less)
- author
- organization
- publishing date
- 2016-07
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Digestive Diseases and Sciences
- volume
- 61
- issue
- 7
- pages
- 2033 - 2040
- publisher
- Springer
- external identifiers
-
- pmid:27007135
- scopus:84961773584
- wos:000379013300033
- ISSN
- 1573-2568
- DOI
- 10.1007/s10620-016-4104-7
- language
- English
- LU publication?
- yes
- id
- 89e7e833-58d5-46b2-812c-8eae45990842
- date added to LUP
- 2016-04-12 11:31:27
- date last changed
- 2024-05-02 22:55:41
@article{89e7e833-58d5-46b2-812c-8eae45990842, abstract = {{<p>BACKGROUND: Accurate inflammation reporting in capsule endoscopy (CE) is important for diagnosis and monitoring of treatment of inflammatory bowel disease (IBD). Fecal calprotectin (FC) is a highly specific biomarker of gut inflammation. Lewis score (LS) was developed to standardize quantification of inflammation in small-bowel (SB) CE images.</p><p>GOALS: Multicenter retrospective study aiming to investigate correlation between LS and FC in a large group of patients undergoing CE for suspected or known small-bowel IBD, and to develop a model for prediction of CE results (LS) based on FC levels.</p><p>STUDY: Five academic centers and a district general hospital offering CE in UK, Finland, Sweden, Canada, and Israel. In total, 333 patients were recruited. They had small-bowel CE and FC done within 3 months.</p><p>RESULTS: Overall, correlation between FC and LS was weak (r s: 0.232, P < 0.001). When two clinically significant FC thresholds (100 and 250 μg/g) were examined, the r s between FC and LS was 0.247 (weak) and 0.337 (moderate), respectively (P = 0.307). For clinically significant (LS ≥ 135) or negative (LS < 135) for SB inflammation, ROC curves gave an optimum cutoff point of FC 76 μg/g with sensitivity 0.59 and specificity 0.41.</p><p>LIMITATIONS: Retrospective design.</p><p>CONCLUSIONS: LS appears to show low correlation with FC as well as other serology markers of inflammation. FC does not appear to be a reliable biomarker for significant small-bowel inflammation. Nevertheless, FC level ≥ 76 μg/g may be associated with appreciable visual inflammation on small-bowel CE in patients with negative prior diagnostic workup.</p>}}, author = {{Koulaouzidis, Anastasios and Sipponen, Taina and Nemeth, Artur and Makins, Richard and Kopylov, Uri and Nadler, Moshe and Giannakou, Andry and Yung, Diana E and Johansson, Gabriele Wurm and Bartzis, Leonidas and Thorlacius, Henrik and Seidman, Ernest G and Eliakim, Rami and Plevris, John N and Toth, Ervin}}, issn = {{1573-2568}}, language = {{eng}}, number = {{7}}, pages = {{2033--2040}}, publisher = {{Springer}}, series = {{Digestive Diseases and Sciences}}, title = {{Association Between Fecal Calprotectin Levels and Small-bowel Inflammation Score in Capsule Endoscopy : A Multicenter Retrospective Study}}, url = {{http://dx.doi.org/10.1007/s10620-016-4104-7}}, doi = {{10.1007/s10620-016-4104-7}}, volume = {{61}}, year = {{2016}}, }